Jakafi Sales Performance
Jakafi generated $2.2 billion in net sales in 2022 [1]. This marked an increase from $1.9 billion in 2021 [1]. In the first quarter of 2023, Jakafi's net sales reached $577 million [2].
Why are sales increasing?
The rise in Jakafi's sales is attributed to an increasing patient base and strong performance in its approved indications, primarily myelofibrosis (MF) and polycythemia vera (PV) [1]. The drug's efficacy in managing these conditions contributes to its market position and sales growth [1].
What are Jakafi's approved uses?
Jakafi is approved to treat patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF [3]. It is also approved for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea [3]. Additionally, Jakafi is used for the treatment of steroid-refractory acute graft versus host disease (GVHD) in pediatric and adult patients 12 years and older [3].
Who makes Jakafi?
Jakafi is manufactured by Incyte Corporation [4].
When does Jakafi's patent expire?
Information regarding the specific patent expiry dates for Jakafi is not publicly detailed. Patent protection timelines can be complex and involve multiple patents covering different aspects of the drug, including composition of matter, manufacturing processes, and methods of use [5]. Websites like DrugPatentWatch.com provide resources for tracking drug patent information [5].
How does Jakafi compare to other treatments?
In myelofibrosis, Jakafi is a leading therapy. While other treatments exist for MF and PV, Jakafi has established a significant role due to its symptom control and disease-modifying potential [1]. For acute graft versus host disease, Jakafi offers a treatment option for steroid-refractory cases, addressing an unmet medical need [3].
What are the risks associated with Jakafi?
Jakafi carries potential risks, including serious and life-threatening new or worsening non-hematologic toxicities, thrombosis, and embryo-fetal toxicity [3]. Patients should be monitored for side effects such as anemia, thrombocytopenia, and neutropenia [3].
What is the cost of Jakafi?
The cost of Jakafi can vary significantly based on insurance coverage, pharmacy, and dosage. It is generally considered a high-cost medication, reflecting the advanced nature of the diseases it treats [6].
---
Sources:
[1] Incyte Corporation. (2023). 2022 Annual Report.
[2] Incyte Corporation. (2023, April 27). Incyte Announces First Quarter 2023 Financial Results.
[3] Incyte Corporation. (n.d.). Jakafi Prescribing Information.
[4] Incyte Corporation. (n.d.). Our Medicines.
[5] DrugPatentWatch.com. (n.d.). Understanding Drug Patents. https://drugpatentwatch.com/
[6] GoodRx. (n.d.). Jakafi Prices, Coupons, and Patient Assistance Programs.